Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +20.21%
#2 B3 (Base) B3 (Base) +8.53%
#3 Fake World Assets Fake World Assets +8.14%
#4 Tornado Cash Tornado Cash +6.81%
#5 Geodnet Geodnet +6.39%
#6 OriginTrail OriginTrail +6.25%
#7 Audiera Audiera +5.37%
#8 Storj Storj +5.26%
#9 Pons Pons +5.16%
#10 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +5.02%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Easywell Biomedicals, Inc. Easywell Biomedicals, Inc.

Easywell Biomedicals, Inc.

1799
Rang in Aktien #20891
Easywell Biomedicals, Inc., together with its subsidiaries, develops,... Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; TLX-011 for treatment of inflammatory lesions of rosacea; TLX-015 a prevention and treatment medicine for postpartum hemorrhage; TLX-018, a hemorrhage treatment drug; TLX-030, an anti-inflammatory medicine; TLX-47, an anti-inflammatory drug; and TLX-024, an anticonvulsant. It also develops TWB-201 for Parkinson patch; TLX-501, a urinary medicine; and TLX-502, a pneumonia medicine. In addition, the company provides thermometers, medical devices, and health food and products. It has a collaborative development agreement with Handa Pharmaceuticals and Handa Neuroscience, LLC for the development of TLX-050 for the treatment of neurological disorders. The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.
Aktienkurs
$0.96033064
Zuletzt synchronisiert: 2026-08-21
Marktkapitalisierung
$119.74M
Veränderung (1 Tag)
0.67%
Veränderung (1 Jahr)
-33.99%
Land
TW
Handel Easywell Biomedicals, Inc. (1799)

Kategorie

Healthcare
Gewinn für Easywell Biomedicals, Inc. (1799)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Easywell Biomedicals, Inc. betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Easywell Biomedicals, Inc. von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
$1.35B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
- -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
- -
FR
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
$26.37M -
US
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
- -
IT